PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S113
Author(s):  
C. Tsai ◽  
C. Chiu ◽  
T. Chou ◽  
L. Li ◽  
K. Chang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Domain ◽  
Small Cell ◽  
Tyrosine Kinase Domain ◽  
Small Cell Lung ◽  
Gefitinib Treatment

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

Lung Cancer ◽  
2005 ◽  
Vol 50 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Rafael Rosell ◽  
Yukito Ichinose ◽  
Miquel Taron ◽  
Carme Sarries ◽  
Cristina Queralt ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Domain ◽  
Small Cell ◽  
Tyrosine Kinase Domain ◽  
Small Cell Lung ◽  
Egfr Gene

scholarly journals Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations

2021 ◽  
Vol 12 (1) ◽  
pp. 164-174
Author(s):  
Hanifeh Mirtavoos-mahyari ◽  
Elham Rismani ◽  
Alireza Sarkar Lotfabadi ◽  
Azizollah Abbasi Dezfouli ◽  
Kambiz Sheikhy ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Domain ◽  
Small Cell ◽  
Dynamics Simulation ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Egfr Tyrosine Kinase

Abstract Nowadays, mutations in the epidermal growth factor receptor (EGFR) kinase domain are studied in targeted therapy of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors including gefitinib and erlotinib. The present study reports a rare case of a patient harboring three simultaneous EGFR mutations (L718A, Q849H, and L858R). The development of erlotinib resistance was detected in the subsequent treatment. Using a computational approach, the current study investigated the conformational changes of wild-type and mutant EGFR's kinase domains in the interaction with erlotinib. Their binding modes with erlotinib were elucidated during molecular dynamics simulation, where higher fluctuations were detected in the mutated forms of the EGFR tyrosine kinase domain. Prediction of stability and functional effect of mutations revealed that amino acidic substitutions have decreased the protein stability as well as the binding affinity to erlotinib. These results may be useful for a recommendation of EGFR mutational analysis for patients with NSCLC carcinoma.

Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer

2004 ◽  
Vol 111 (2) ◽  
pp. 259-263 ◽  
Author(s):  
Ulrich-Peter Rohr ◽  
Nina Rehfeld ◽  
Lucy Pflugfelder ◽  
Helene Geddert ◽  
Wolfram Müller ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Independent Prognostic Factor ◽  
Small Cell Lung ◽  
Kinase C
Sign in / Sign up

Export Citation Format

Share Document